AFRIPLEX STRENGTHENS ITS POSITION IN THE MARKETPLACE AFTER SUCCESSFUL ACQUISITION!
Afriplex is proud to announce that it recently acquired the Edelweiss Pharmaceutical business and is in the process of taking over the manufacturing of all solid dosage forms, namely tablets and capsules.
In anticipation of increased business moving into their facility, Afriplex invested in their production plant and staff to ensure they have the infrastructure required to deliver a high level of service and good quality products to both their new and existing clients. Expansions will be completed by the end of February 2017.
“Afriplex’s strategy is to maintain leadership in the complementary medicine market in South Africa. The acquisition of Edelweiss Pharmaceuticals’ business perfectly matches this strategy as it complements our existing business and offers our clients access to a wide range of products and services. Together with our subsidiaries, Afriplex Botanicals and Afriplex Food & Beverage, Afriplex now holds a strong foothold in the Food, Beverage and Pharmaceutical industries in South Africa. This is an excellent platform for further growth in the country and beyond. More acquisitions will follow”, says Danie Nel, Managing Director of Afriplex.
James Gibson, owner of Edelweiss Pharmaceuticals, describes Afriplex’s GMP compliant facility as “a magnificent plant” and sees the acquisition as a great solution for their clientele. Edelweiss clients will benefit from the acquisition by having access to Afriplex’s own range of botanical API’s, research and development services, quality assurance procedures as well as assistance with CTD compilation, including in-house stability testing.
Afriplex welcomes all Edelweiss clients on board, and gives the assurance of their full support during this transition period.